drugset / Trial / NCT00884546
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-833923 administered alone, in combination with lenalidomide plus dexamethasone, or in combination with bortezomib in subjects with relapsed or refractory multiple myeloma.
Timeline
- Start
- 2009-07
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-833923 | Small molecule | 30 mg | Oral |
| Comparator | Bortezomib | Small molecule | — | Intravenous |
| Comparator | Dexamethasone | Small molecule | 40 mg | Oral |
| Comparator | Lenalidomide | Other / unclassified | — | Oral |